The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

retinalgenix.com

Founded Year

2017

Stage

IPO | IPO

Total Raised

$50K

Date of IPO

3/8/2022

Market Cap

0.10B

Stock Price

7.15

About RetinalGeniX Technologies

RetinalGeniX Technologies (OTCQB: RTGN) is a medical device company focused on commercializing ultra-wide imaging technologies to examine the periphery of the retina to detect early signs of diabetic retinopathy.

RetinalGeniX Technologies Headquarter Location

1450 North Mcdowell Boulevard Suite 150

Petaluma, California, 94954,

United States

(415) 578-9583

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing RetinalGeniX Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

RetinalGeniX Technologies is included in 4 Expert Collections, including Diabetes.

D

Diabetes

1,750 items

M

Medical Devices

8,442 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

2,394 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

H

Health IT

7,900 items

Latest RetinalGeniX Technologies News

RetinalGeniX Technologies, Inc. Acquires DNA/GPS Inc.

Jul 6, 2022

. Acquisition of DNA-Based "GPS" Genetic Testing Combines with RTGN's High Resolution Retinal Imaging Technologies Seeks to Revolutionize Diagnosis of Systemic Diseases July 06, 2022 08:00 ET Petaluma, California, UNITED STATES PETALUMA, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), announced today the acquisition of DNA/GPS Inc., a pharmacogenetics company based in Tampa, Florida and founded by Dr. Larry Perich. RetinalGeniX now has the rights to the platform technology designed by Dr. Perich, which allows healthcare providers to use retinal imaging and genetic mapping to monitor and screen patients from their homes to provide diagnoses of systemic diseases including heart disease, Alzheimer’s, dementia, Parkinson's and more. “We believe this platform to be a breakthrough in advanced retinal imaging and genetic mapping that could become a new standard for the diagnosis of systemic disease and could replace expensive and time-consuming procedures such as CT, MRI, and PET at a much lower cost. The RetinalGeniX DNA/GPS platform offers an opportunity to bring testing away from laboratories and hospitals and into primary care centers, where it could be handled by practitioners at a cost that is a fraction of that of a CT scan, an MRI or an echo machine,” said RetinalGeniX CEO Jerry Katzman, MD. The new platform is being designed to enable us to determine the right patients to screen and should assist healthcare providers to choose the most effective early interventions. This is possible because manifestations of disease are most often seen in the eye. It is widely acknowledged that the eyes are a window to systemic health. It is possible to observe correlations between damage in the retina and kidney disease, high blood pressure and heart problems. The emergence of high-resolution imaging in modalities and the progress of artificial intelligence, in particular, deep learning, have opened up new pathways to potentially identify science and protectors of systemic disease through the retina. “We welcome Dr. Perich to our advisory board as a tremendous asset to our initiative to prevent blindness, promote home monitoring and establish retinal imaging and pharmacogenetics as the new standard," said Dr. Katzman. With the guidance of RetinalGeniX DNA/GPS, the company intends to focus on patients that have genetic predisposition to multiple systemic diseases. For more information, visit: www.retinalgenix.com . Safe Harbor Statement This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements and include statements regarding revolutionizing the diagnosis of systemic diseases, launching a breakthrough in advanced retinal imaging and genetic mapping that could become the new standard for the diagnosis of systemic disease, the platform having the potential to replace expensive and time-consuming procedures such as CT, MRI, and PET at a much lower cost, the platform determining the right patients to screen and choosing the most effective early interventions, offering the opportunity to bring testing away from laboratories and hospitals and into primary care centers, where it could be handled by practitioners at a cost that is a fraction of that of a CT scan, an MRI or an echo machine and focusing on patients that have genetic predisposition to multiple systemic diseases. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to deploy the platform as planned and provide cost-effective and definitive early diagnoses for patients, the ability of the platform to provide diagnoses of systemic diseases such as heart disease, dementia, Parkinson's, Alzheimer's, and more, the Company’s ability to establish the platform as the new standard for the diagnosis of systemic disease, the ability of the platform to replace expensive and time-consuming procedures such as CT, MRI, and PET at a much lower cost, the ability to enhance the screening process of which patients would benefit the best for a retinal imaging analysis, the ability to use retinal imaging to bring the testing away from laboratories and hospitals to primary care centers, and the risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. Contact

RetinalGeniX Technologies Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

RetinalGeniX Technologies Rank

  • When was RetinalGeniX Technologies founded?

    RetinalGeniX Technologies was founded in 2017.

  • Where is RetinalGeniX Technologies's headquarters?

    RetinalGeniX Technologies's headquarters is located at 1450 North Mcdowell Boulevard, Petaluma.

  • What is RetinalGeniX Technologies's latest funding round?

    RetinalGeniX Technologies's latest funding round is IPO.

  • How much did RetinalGeniX Technologies raise?

    RetinalGeniX Technologies raised a total of $50K.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.